Intradialytic Kinetics of Cardiac Biomarkers during High-Flux Hemodialysis and Postdilution Hemodiafiltration
Kidney360 · 2026-10 · 7 (10) · 2291-2302
DOI: 10.34067/kid.0000001284 ↗Abstract
Key Points High-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, and N -terminal pro–B-type natriuretic peptide are reduced by hemodiafiltration, increasing the risk of potential misinterpretation in patients undergoing dialysis. Measuring these biomarkers during or immediately after dialysis may yield falsely low concentrations. Clinicians should consider the timing of the most recent dialysis session when interpreting cardiac biomarkers for diagnostic purposes. Background There are limited data on how hemodialysis influences cardiac biomarker concentrations. This study aimed to investigate concentration changes of high-sensitivity troponin I and T, and N -terminal pro–B-type natriuretic peptide (NT-proBNP) before, during, and after hemodialysis and hemodiafiltration (HDF), and to compare these changes between the two dialysis modalities. Methods Randomized crossover study including 23 stable patients treated with hemodialysis/HDF. Patients were randomized to start with high-flux hemodialysis or postdilution HDF, had a washout period of 1–3 weeks, and then crossed over to receive the other modality. Blood samples were collected before dialysis, after 10, 30, 60, 120, 180, and 240 minutes of dialysis, and 30 minutes postdialysis. In addition, spent dialysate was collected after 120 minutes of dialysis. Linear mixed-effects models were used to investigate concentration changes and compare dialysis modalities. Results High-sensitivity troponin I and high-sensitivity troponin T were not influenced by hemodialysis; however, HDF resulted in a significant decline in both biomarkers. At the end of dialysis, the change was −7.7 ng/L (95% confidence interval [CI], −12.3 to −3.1) for high-sensitivity troponin I and −23.4 ng/L (95% CI, −31.8 to −15.0) for high-sensitivity troponin T. NT-proBNP was significantly reduced with both modalities, with a change of −2954 ng/L (95% CI, −4974 to −934) in hemodialysis and −5161 ng/L (95% CI, −7231 to −3092) in HDF. All biomarker concentrations were significantly lower with HDF compared with hemodialysis at the end of dialysis. Conclusions High-sensitivity troponin I, high-sensitivity troponin T, and NT-proBNP were significantly reduced with HDF in asymptomatic patients treated with dialysis. Hemodialysis reduced NT-proBNP. Cardiac biomarker levels are influenced by dialysis and treatment modality, which could lead to potential misinterpretation. This emphasizes that time since the last dialysis session should be considered when interpreting cardiac biomarkers for diagnostic purposes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT06526702.
EUVIMED